Neogen Chemicals Ltd Q2 Revenue Rises 42% to Rs 296 Crore

Neogen Chemicals Ltd reported Q2 FY27 consolidated revenue of Rs 296 crore, up 42% year-on-year, while consolidated EBITDA increased 51% to Rs 45 crore as base-business volumes expanded and battery chemical revenue reached Rs 37 crore.

What did Neogen Chemicals Ltd report in Q2 FY27?

Neogen Chemicals Ltd reported broad-based growth in the September-quarter earnings call, with consolidated revenue rising to Rs 296 crore from the corresponding quarter a year earlier. Management attributed the increase to consistent volume expansion across core segments, including growth in organolithium, as well as the ramp-up at its battery chemicals business.

Consolidated EBITDA rose 51% year-on-year to Rs 45 crore, outpacing revenue growth. On a standalone basis, EBITDA increased 54% to Rs 54 crore, with a margin of 18.6%. The difference between standalone and consolidated profitability reflects initial fixed-cost absorption at Neogen Ionics, according to management.

Managing Director Dr. Harin Kanani said the company had shifted towards applications with better demand visibility and higher volumes. The earnings call was attended by Non-Executive Chairman Anurag Surana, Dr. Kanani and Chief Financial Officer Gopikrishnan Sarathy.

Which business segments drove Neogen Chemicals Ltd's growth?

Neogen Chemicals Ltd's organic chemicals segment generated Rs 238 crore of revenue in Q2 FY27, representing year-on-year growth of 29%. The inorganic chemicals segment recorded substantially faster growth of 140%, with quarterly revenue of Rs 58 crore.

The battery chemicals operation, housed in Neogen Ionics, was another important contributor. Revenue from this business rose to Rs 37 crore in Q2 FY27 from Rs 5 crore in Q2 FY26. Management said the quarterly figure equalled the battery business's full-year sales in the previous financial year.

This acceleration is material because the consolidated results continue to carry the initial fixed costs of the newer operation. Higher revenue and capacity utilisation at Neogen Ionics could therefore remain important variables for consolidated profitability as the business expands.

What were the key Q2 FY27 financial figures?

Neogen Chemicals Ltd's reported financial metrics show revenue growth across its principal chemical businesses and faster growth in consolidated EBITDA. The following table summarises the main figures disclosed during the call.

The segment figures of Rs 238 crore for organic chemicals and Rs 58 crore for inorganic chemicals add up to the reported consolidated revenue of Rs 296 crore. The figures indicate that the legacy business remained the larger contributor, while inorganic and battery-linked operations delivered the sharper rate of expansion.

Why does the Neogen Ionics ramp-up matter to investors?

Neogen Ionics matters because it is currently scaling up and its early fixed costs are affecting the consolidated profit profile. Management specifically noted that standalone profitability was stronger because consolidated results include this initial cost absorption.

Battery chemical revenue of Rs 37 crore compared with Rs 5 crore a year earlier shows that commercial activity has increased rapidly. However, management also indicated that revenue scale-up and capacity utilisation are still ramping up. Customer commissioning and approvals remain relevant to battery-business utilisation and margins.

For investors, the result separates two developments. The established chemical businesses supplied most of quarterly revenue and continued to grow, while Neogen Ionics added a newer source of sales but is still moving towards fuller operating utilisation. This makes segment execution and profitability progression important factors to monitor in later disclosures.

What outlook has management indicated for the base business?

Neogen Chemicals Ltd said its base business is expected to cross Rs 1,000 crore of revenue in FY27. It also indicated expected growth of 10% to 15% for FY28, with a revenue target range of Rs 1,100 crore to Rs 1,200 crore for the base business.

The company also referred to QIP proceeds, insurance recoveries and capacity ramp-ups as factors supporting its expansion plans. No amounts for the QIP proceeds or insurance recoveries were disclosed in the supplied call material, so their direct financial contribution cannot be quantified from the available information.

The FY27 quarter therefore provides evidence of stronger current revenue and EBITDA performance, while the stated base-business outlook sets a reference point for future execution. The pace of Neogen Ionics ramp-up, customer approvals and capacity utilisation will remain central to assessing whether newer operations contribute more fully to consolidated earnings.

Conclusion

Neogen Chemicals Ltd delivered a stronger Q2 FY27, with consolidated revenue rising 42% to Rs 296 crore and EBITDA increasing 51% to Rs 45 crore. Organic chemicals remained the largest revenue contributor, while inorganic chemicals and the battery chemicals operation recorded faster growth. The results also show that Neogen Ionics is becoming a meaningful revenue contributor even as it absorbs initial fixed costs.

Investors will next watch progress towards management's expectation of base-business revenue exceeding Rs 1,000 crore in FY27 and its FY28 target range of Rs 1,100 crore to Rs 1,200 crore. Updates on battery chemical customer commissioning, approvals, utilisation and margins will be relevant to the consolidated earnings trajectory.